中国中药(00570.HK) 发盈警，预计2024年度溢利净额按年下降90%-100%；及经调整净利净额下降50%-60%。主要因集采降价、市场竞争加剧及药材成本偏高等多重因素影响中药配方颗粒业务销售规模及盈利水平；信用减值、商誉减值及厂房减值增加；及部分附属公补缴税款对溢利净额造成较大影响。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-15 16:25。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/08/28 | 中期业绩 | 无派息 |
| 2024/03/21 | 末期业绩 | 无派息 |
| 2023/08/29 | 中期业绩 | 无派息 |
| 2023/03/24 | 末期业绩 | 股息：港元 0.0518 (约相等于 人民币 0.0455元) |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.